We asessed factors which affect cisplatin concentrations in human surgical tumour specmen. al., 1994a; Stewart, 1994) . For many chemotherapy drugs, only low concentrations are found in normal brain and cerebrospinal fluid (CSF), because of the BBB and blood-CSF barrier, but the barrier is often largely disrupted in patients with brain tumours (Blasberg and Groothuis, 1986) . In animal models, the degree of BBB disruption varies from one type of tumour to another and between parts of the same tumour (Groothuis et al., 1981; Blasberg and Groothuis, 1986) . Lower concentrations of chemotherapy drugs (Levin et al., 1972; Tator, 1976; Groothuis et al., 1981) and lower capillary permeability (Hasegawa et al., 1983) It has also been argued that resistance of IC tumours may be due in part to invasion of tumour cells into the brain adjacent to tumour (BAT), where the BBB is more intact, and where drug concentrations are lower than in the main body of the tumour (Levin et al., 1975) . However, the importance in brain tumour chemotherapy of resistance of tumour cells in the BAT remains controversial. Since even small numbers of tumour cells may induce leakiness in local blood vessels (Stewart et al., 1987), small tumour deposits in the BAT could result in a very localised increase in drug concentrations, and it is uncertain how drug concentrations compare in individual tumour cells in BAT vs the main tumour body.
It remains uncetain if the blood-brain barrier (BBB) plays a major role in the resistance of intracranial (IC) tumours to chemotherapy (reviewed in Stewart et al., 1994a; Stewart, 1994) . For many chemotherapy drugs, only low concentrations are found in normal brain and cerebrospinal fluid (CSF), because of the BBB and blood-CSF barrier, but the barrier is often largely disrupted in patients with brain tumours (Blasberg and Groothuis, 1986) . In animal models, the degree of BBB disruption varies from one type of tumour to another and between parts of the same tumour (Groothuis et al., 1981; Blasberg and Groothuis, 1986) . Lower concentrations of chemotherapy drugs (Levin et al., 1972; Tator, 1976; Groothuis et al., 1981) and lower capillary permeability (Hasegawa et al., 1983) have been reported in animal IC tumours compared with subcutaneous tumours. Moreover, some studies have reported that drug distribution is far more uniform in extracranial (EC) tumours than in IC tumours (Tator, 1976; Groothuis et al., 1981) , and it has been argued that this may result in reistance in the areas of IC tumours that achieve only low drug concentrations. However, data supporting a difference between IC and EC tumours with respect to uniformity of drug distribution are limited, and other studies have suggested that drug distribution also varies markedly within EC tumours (Rowe-Jones, 1969 It has also been argued that resistance of IC tumours may be due in part to invasion of tumour cells into the brain adjacent to tumour (BAT) , where the BBB is more intact, and where drug concentrations are lower than in the main body of the tumour (Levin et al., 1975) . However, the importance in brain tumour chemotherapy of resistance of tumour cells in the BAT remains controversial. Since even small numbers of tumour cells may induce leakiness in local blood vessels (Stewart et al., 1987) , small tumour deposits in the BAT could result in a very localised increase in drug concentrations, and it is uncertain how drug concentrations compare in individual tumour cells in BAT vs the main tumour body.
We have studied several chemotherapy drugs with respect to the concentrations reached in human IC tumours (reviewed in Stewart et al., 1994a , Stewart, 1994 . Concentrations in IC tumours appeared to be similar to those in EC tumours for cisplatin, phosphonacetyl-L-aspartate, 4'-(9-acridinylamino)-methanesulphon-m-aniside (AMSA), pentamethylmeamine, doxorubicin and vinblasine. Concentrations of etoposide and mitoxantrone in IC tumours were somewhat lower than in EC tumours. Since no EC tumour samples were available, comparisons were not possible for a variety of other agents, but for most of these drugs potentially cytotoxic concentrations were achieved in human IC tumours. Low drug concentrations in normal brain and CSF did not preclude high concentrations in IC tumours.
In this paper, we report the results of further studies of human tumour accumulation of the chemotherapy drug cisplatin. These studies were done since our earliest studies of surgical specimens had looked only at IC tumours. While our later autopsy studies had looked at both IC and EC tumours, there were differences between patients with respect to drug doses, time from last treatment to death, concurrent drugs, (Gaffin, 1979) . After cooling, the digests were washed quantitatively into 20 ml glass beakers containing distilled deionised water, and the contents evaporated to dryness on a hot plate. The residues were allowed to dry, and were then dissolved in 1-2ml or 5ml of 0.5% (v/v) Using these independent variabks, we constructed several multiple stepwise regression models to assess which factors most closely correlated with tumour platinum concentrations after correction for associations between the independent variables. The model that best fitted our data is presented in For intracerebral tumours, platinum concentrations correlated with intensity of oedema on CT scan (r = 0.59, P = 0.01) ( Table V) . The association of oedema intensity with tumour platinum concentration continued to approach significae (P = 0.06) even after correction for tumour source by stepwise multiple regression analysis. Of 
D6cussion
These studies were done with a subtherapeutic cisplatin dose since we wished to (and did) avoid toxicity. The drug was being given strictly for the purposes of pharmacology studies with no therapeutic intent. While it is highly unlikely that exposure to a single low dose of cisplatin would result in long-term cisplatin resistance, patients suspected preoperatively of having a chemotherapy-curable tumour type were specificaDly excluded to preclude the possibility of resistance induction. Hence, it is possible that our results would not apply to tumour types that are generally highly responsive to cisplatin.
We feel that the results obtained with these low-dose studies may well be applicable to the higher doses usually used clinicaly since the tumour platinum concentrations noted in this study were in the expected range when compared with our previous studies using higher doses of cisplatin (reviewed in Stewart et al., 1994a; Stewart, 1994) , since cisplatin plasma pharmacokinetics is linear with dose (Vermorken et al., 1986) , and since cisplatin accumulation in cells in vitro is linear with dose and is not saturable (Mann et al., 1990) .
As in our previous studies, we measured only total platinum concentrations in tissues. It is probable that a Model: adjusted R2 = 0.39c; P = 0.002 "The square root of chloride was used since it (unlike chloride itself) conformed to a normal distribution, as required by multiple stepwise regression analysis. bType LMM = the group consisting of primary brain lymphomas, meningiomas and medulloblastomas. CThe adjusted R2 increased to 0.45 with the inclusion of 'other' tumour sources along with the variables shown, but the P-value for 'other' did not quite reach statistical significance (P = 0.057), and the Pvalue for bilirubin increased to 0.07 with the inclusion of 'other' sources. The data were equally well fitted by a model that included each of tumour sources glioma, lung and head/neck (each of which individually had a negative correlation with tumour platinum concentration, with P <0.05), serum calcium, chloride and bilirubin. With the inclusion of these three tumour sources, the P-value for bilirubin increased to 0.10. number of different free and bound platinum species were present. Hence, it is possible that the conclusions we have drawn regarding total platinum concentrations do not also apply to the active species or to binding of drug to cytotoxcity-related intracellular targets. Despite this, we feel that the information gained is important, since we have previously found that both isplatin efficacy and toxicity are proportional to total tissue platinum concentrations (reviewed in Stewart, 1994a; Stewart, 1994) , and since several cisplatin metabolites are cytotoxic (Goel and HowelL 1989). Based on these earlier observations, the concentration of active species is probably geneally proportional to the total platinum content.
We made no attempt to correct tumour platinum concentrations for platinum concentrations in plasma since blood generally accounts for kss than 5% of total tumour volume, and since tumour platinum concentrations did not correlate with any plasma platinum pharmacokinetic parameters. In addition, when we divided tumour platinum concentrations by the area under the concentration vs time curve from time 0 to the time of tumour removal to correct for possible differences in exposure of the tumours to cisplatin, essentially the same factors correlated with the resulting value as with raw values of tumour platinum concentration (data not shown).
In previous autopsy studies, we found no evidence that drug concentrations in IC tumours were any lower than those in EC tumours (reviewed in Stewart et al., 1994a; Stewart, 1994) . However, in these previous studies, there was substantial variability between patients with respect to drug dose, time from last treatment to death, etc. In this study, drug doses were the same for all patients, and even after correcting for the effect of other factors by multiple stepwise regression analysis tumour platinum concentrations did not vary significantly over the relatively narrow time span of sample acquisition in this study. As in our previous studies, we found no evidence in this study that entry of asplatin into IC tumours was any less than entry into EC tumours.
For reasons that are unclear, gliomas had lower platinum concentrations than did any other IC or EC tumours. We have previously noted higher or lower drug concentrations in gliomas than in other IC tumours for other compounds as well (reviewed Stewart et al., 1994a; Stewart, 1994) . Differences in this study may have been partially due to the particularly low tumour platinum concentrations noted in low-grade gliomas, but high-grade gliomas also had lower platinum concentrations than did other tumours. It is possible that differences in cell membranes could partially account for these results. For example, the fatty acid content of cell membranes may alter cisplatin uptake and resistance (Tunmer-Bosscha et al., 1989) . While the high cisplatin uptake into non-gliomas IC tumours indicates that the BBB is not a major factor in cisplatin uptake into IC tumours, differences observed between low-grade vs high-gade gliomas suggest that BBB phenomena may, nevertheless, be playing a minor role. While the BBB is largely disrupted within intracranial tumours (Groothuis et al., 1981; Blasberg and Groothuis, 1986) , degree of contrast enh nt on CT scans suggests that it may be less disrupted in low-grade than high-grade gliomas (Tchang et al., 1977) . While some evidence suggests that the BBB plays a role in the resistance of human IC tumours to chemotherapy, there are alternative explanations for much of the evidence (reviewed in Stewart et al., 1994a; Stewart, 1994) . Tumour cell resistance is probably a far more important reason for chemotherapy failure than is inability of the drug to cross the intact BBB, and any barrier might make relatively little difference for a highly cytotoxic drug (Wodinsky et al., 1977) . Hence both we (reviewed in Stewart et al., 1983 , 1986a -c, 1987a , 1989a , 1990a ,b, 1994ac, Feun et al., 1985 Stewart, 1987a Stewart, ,b, 1989 Stewart, , 1994 and several other investigators (reviewed in Kolaric et al., 1981; Rosner et al., 1983; Kantarajian et al., 1984; Stewart, 1989) (Shapiro, 1983) . For lipid-insoluble drugs, cell membrane factors may be more important determinants of drug entry than is blood flow (Dedrick et al., 1975) . The lack of a correlation of estimated tumour size with tumour platinum concentration, the low cisplatin concentrations seen in normal central nervous system and low-grade gliomas and the somewhat higher tumour platinum concentrations we observed in necrotic compared with viable tumours suggest that this is so for cisplatin.
Cisplatin may enter tumour cells by both passive diffusion and active transport (Gross and Scanlon, 1986; Kelley and Rozencweig, 1989) , and also may be actively pumped out of some cells (Mann et al., 1990) . The positive correlations in multivariate analysis of tumour platinum concentrations with serum calcium and chloride levels suggest that the active transport of cisplatin into or out of cells may be affected by these ions, or that these ions may alter passive diffusion of cisplatin across cell membranes by altering membrane potentials or membrane lipid metabolism. Of interest, we have recently found that cisplatin uptake into a human lung adenocarcinoma cell line also increases with increasig calcium concentrations over a physiological range (Stewart et al., 1994b) . Furthermore, we have previously noted that serm calcium levels correlated positively with cisplatin neurotoxicity (Stewart et al., 1989b) , but correlated negatively with cisplatin renal toxcity (Stewart et al., 1987b) , suggesting that the effect of calcium on tissue platinum concentrations could vary from one tissue type to another. Other ions such as copper and selenium also appear to reduce cisplatin renal toxicity (Berry et al., 1984) , but cisplatin uptake into our human lung adenocarcinoma cell line increased with increasing copper concentrations over a physiological range (Stewart et al., 1994b) . It was not possible to measure serm copper levels as part of this study. Osmolarity also affects cisplatin cell uptake and cytotoxicity (Goel and Howel, 1989) .
It is unknown whether the correlation between tumour platinum concentrations and serum bilirubin is of any physioogical signi . We previously noted that high serum bilirubin is associated with increased cisplatin nephrotoxicity (Stewart et al., 1987b) . Liver attains higher platinum concentrations than does almost any other organ in the human body (Stewart et al., 1982) . One might speculate that hepatic conditions associated with increased serum bilirubin levels also result in increased hepatic sequestration of cisplatin. While such a hypothesis could explain the observed negative association between serum biiirubin levels and tumour platinmum concentrations, it would not explain our previous observition of a positive association between high serum bilirubin and augmented cisplatin nephrotoxicity (Stewart et al., 1987b) . Moreover, patients with hyperbilirubinaemia had higher kidney cortex platinum concentra-tions than did patients with normal serum bilirubin levels (Stewart et al., 1994) , indicating that, as with calcium, billrubin could have differing effects on cisplatin uptake into different types of tissue.
Perhaps the most likely explanation for the apparent effect of bilirubin on tumour cell cisplatin uptake is that factors associated with high bilirubin alter cellular passive drug uptake by altering cell membrane lipid characteristics. We (Popovic et al., 1992) and others (Timmer-Bosscha et al., 1989) have found differences between cisplatin-sensitive and -resistant cells with respect to cell membrane characteristics. We have also found that cisplatin and its aquated species interact chemically with some cell memnbrane lipid components, and that phospholipid content may affect the ability of cisplatin to diffuse passively through model membranes (Taylor et al., 1992 (Taylor et al., , 1993 .
It is also possible that each of calcium, chloride and bilirubin could have affected tumour cisplatin concentrations by altering drug elimination, etc. However, this is unlikely to be the case, in light of the fact that there was no significant correlation between any plasma pharmacokinetic parameter and tumour platinum concentrations.
In summary, the accumulation of cisplatin in tumours may perhaps be more related to the tissue of origin of the tumour and to physiological conditions than to whether the tumour is intracranial or extracranial. We plan to conduct further studies of factors affecting tumour cell cisplatin uptake.
Abbreviatioi AUC, area under the concentration vs time curve; BAT, brain adjacent to tumour; BBB, blood-brain barrier; CSF.
cerebrospinal fluid, CT, computerised axial tomography; EC, extracranial; IC, intracranial; NSCLC, non-small-cell lung cancer.
